Anika Therapeutics | ANIK - Operating Expenses

Stock Price
14.57
Daily Change
0.29 2.03%
Monthly
13.92%
Yearly
-3.89%
Q1 Forecast
13.43

Anika Therapeutics reported $29.97M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Abbott USD 9.21B 17M Dec/2025
Agenus USD 19.81M 293.94M Dec/2025
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
Anika Therapeutics USD 29.97M 116.84M Dec/2025
Arrowhead Research USD 223.22M 10.86M Dec/2025
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 513.55M 109.86M Dec/2025
Integra LifeSciences USD 368.92M 668.65M Dec/2025
Intrexon USD 61.56M 26.1M Jun/2024
J&J USD 18.97B 2.38B Dec/2025
Karyopharm Therapeutics USD 61.82M 3.24M Dec/2024
Ligand Pharmaceuticals USD 8.29M 32.17M Sep/2025
MacroGenics USD 53.32M 13.68M Dec/2025
Merit Medical Systems USD 339.74M 1.8M Dec/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 10.51B 1.21B Dec/2025
Smith & Nephew USD 2.52B 84M Dec/2025
Stryker USD 5.2B 505M Dec/2025
Surmodics USD -245.35M 363.49M Sep/2024
Veracyte USD 116M 7.24M Dec/2025
Xencor USD 81.86M 13.35M Dec/2025
Zimmer Biomet Holdings USD 1.94B 277.8M Dec/2025